Patents Examined by Gregg Polansky
  • Patent number: 10799472
    Abstract: Compositions and methods for treating parasitic infections are provided. The compositions can include two or more of alpha-pinene, linalyl acetate, para-cymene, and thymol octanoate. The compositions and methods can be effective against, for example, protozoan parasites, helminthic parasites, nematodes, trematodes, flukes, cestodes, and the like. Formulations made from the composition are also provided, including formulations in which the composition is combined with a carrier to form a food product and/or a drink. The formulation can be, for example, a suspension, a solution, or an emulsion in an oily or an aqueous carrier; like wise, the composition can be provided in an encapsulated or microencapsulated form.
    Type: Grant
    Filed: July 30, 2018
    Date of Patent: October 13, 2020
    Assignee: TyraTech, Inc.
    Inventors: Essam Enan, Ahmad Akashe, Anilkumar Gaonkar, Leslie West
  • Patent number: 10799590
    Abstract: A composition comprising a bitter tastant and at least one sophorolipid and optionally a carrier; wherein the composition is edible and wherein the bitter taste of said bitter tastant is reduced. A method of reducing bitter taste attributed to a bitter tastant in an edible composition, said method comprising adding to said edible composition an effective amount of at least one sophorolipid and optionally a carrier; such that any bitter taste induced by the bitter tastant is reduced.
    Type: Grant
    Filed: October 30, 2018
    Date of Patent: October 13, 2020
    Assignees: The United States of America, as represented by the Secretary of Agriculture, Monell Chemical Senses Center
    Inventors: Daniel Solaiman, Richard D Ashby, Mehmet Hakan Ozdener, Alexander Bachmanov
  • Patent number: 10793571
    Abstract: The present invention provides compounds of Formula (II) (e.g., compounds of Formula (I)), and pharmaceutically compositions thereof. Compounds of Formula (II) are believed to be binders of bromodomains and/or bromodomain-containing proteins (e.g., bromo and extra terminal (BET) proteins). Also provided are methods, uses, and kits using the compounds and pharmaceutical compositions for inhibiting the activity (e.g., increased activity) of bromodomains and/or bromodomain-containing proteins and for treating and/or preventing in a subject diseases associated with bromodomains or bromodomain-containing proteins (e.g., proliferative diseases, cardiovascular diseases, viral infections, fibrotic diseases, metabolic diseases, endocrine diseases, and radiation poisoning). The compounds, pharmaceutical compositions, and kits are also useful for male contraception.
    Type: Grant
    Filed: February 2, 2015
    Date of Patent: October 6, 2020
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: James E. Bradner, Nathanael S. Gray, Jun Qi, Michael R. McKeown, Dennis Buckley
  • Patent number: 10772886
    Abstract: N-(2-((2,3-difluorobenzyl)thio)-6-(((2R,3S)-3,4-dihydroxybutan-2-yl)oxy)pyrimidin-4-yl)azetidine-1-sulfonamide (compound 3) and N-(6-(((2R,3S)-3,4-dihydroxy butan-2-yl)oxy)-2-((4-fluorobenzyl)thio)pyrimidin-4-yl)-3-methyl-azetidine-1-sulfonamide (compound 4) are known chemokine modulators and are therefore useful in the treatment of diseases/conditions in which modulation of chemokine receptor activity is beneficial. In particular, provided herein are compositions and methods for the treatment and prevention of gout.
    Type: Grant
    Filed: March 9, 2017
    Date of Patent: September 15, 2020
    Assignee: ARDEA BIOSCIENCES, INC.
    Inventors: Payal Nanavati, Jeffrey Miner
  • Patent number: 10758501
    Abstract: Described herein is the use of bisamidoximes compounds for the treatment of cancer. In preferred embodiments, combinations of two or more bisamidoximes or combinations of a bisamidoxime and another anti-cancer agent were found to be effective against various types of cancer cells.
    Type: Grant
    Filed: October 2, 2018
    Date of Patent: September 1, 2020
    Assignee: Texas Woman's University
    Inventors: Michael Bergel, James E. Johnson, Debra Dolliver, Sudheer Dhanireddy, Amon Gekombe
  • Patent number: 10752606
    Abstract: The invention provides compounds of Formula (I), and their use in methods for treating or preventing a protozoan infection in a subject using a compound of Formula (I). The invention also provides the use of a compound of Formula (I) in the manufacture of a medicament for the treatment of a protozoan infection in a subject. The invention further provides a medical device when used in a method of treating or preventing a protozoan infection in a subject and to a medical device comprising the composition of the invention.
    Type: Grant
    Filed: November 29, 2019
    Date of Patent: August 25, 2020
    Assignee: NEOCULI PTY LTD.
    Inventors: Stephen Page, Andrew Stevens, Adam McCluskey, Martine Keenan, Rebecca Abraham
  • Patent number: 10716771
    Abstract: The present invention relates to a biguanide derivative compound capable of effectively preventing and treating immune diseases. The biguanide-based derivative compound according to the present invention inhibits the generation of IL-17 and TNF-?, which are inflammatory cytokines, increases the activity of regulatory T cells having an immunomodulatory function, and exhibits excellent therapeutic effects in animal models of immune diseases. Accordingly, the biguanide-based derivative compound can be usefully used as an immunosuppressant or a pharmaceutical composition capable of preventing or treating various immune diseases, such as autoimmune diseases, inflammatory diseases, and transplant rejection, caused by the dysregulation of immune responses.
    Type: Grant
    Filed: June 19, 2019
    Date of Patent: July 21, 2020
    Assignee: THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC CORPORATION FOUNDATION
    Inventors: Mi-La Cho, Chul-Woo Yang, Dong-Yun Shin, Min-Jung Park, Seon-Yeong Lee, Sung-Hee Lee, Eun-Ji Yang, Hye-Jin Son, Eun-Kyung Kim, Jae-Kyung Kim
  • Patent number: 10702490
    Abstract: Cysteine compositions comprising less than about 400 ?g/L of aluminum. For example, solutions of cysteine comprising a pharmaceutically acceptable solvent, cysteine, and less than about 145 ?g/L of aluminum, wherein the solution is devoid of visible particulate matter. Cysteine compositions described herein may be suitable for injection. For example, disclosed cysteine solutions may be provided intravenously to meet amino acid nutritional requirement in individuals receiving total parenteral nutrition. Also provided are processes for preparing cysteine compositions, and methods for providing cysteine to individuals in need thereof.
    Type: Grant
    Filed: November 7, 2019
    Date of Patent: July 7, 2020
    Assignee: Avadel Legacy Pharmaceuticals, LLC
    Inventors: Angela Sutterer, Jill Simpson, Gauthier Pouliquen, Alain Constancis, Pierre Danner
  • Patent number: 10695318
    Abstract: This invention relates to compositions, and methods of use thereof, for (i) enhancing executive cognitive function(s) (for example, decision making, planning, working memory, multitasking, judgment, numerical problem-solving, reading comprehension), and/or (ii) increasing blood flow in brain vasculature, comprising administering to a subject in need thereof, certain polyphenols such as flavanols, procyanidins, or pharmaceutically acceptable salts or derivatives thereof.
    Type: Grant
    Filed: January 7, 2019
    Date of Patent: June 30, 2020
    Assignee: MARS, INCORPORATED
    Inventors: Stephen French, Amar P Inamdar, Ian Andrew MacDonald, Susan T Francis
  • Patent number: 10688099
    Abstract: Described herein are methods for modulating the amount of a gene product and compounds for use in such methods. More particularly, described herein are methods for modulating the amount of an RNA transcript or protein product as the result of gene expression and compounds for use in such methods.
    Type: Grant
    Filed: January 15, 2019
    Date of Patent: June 23, 2020
    Assignee: PTC Therapeutics, Inc.
    Inventor: Nikolai Naryshkin
  • Patent number: 10660878
    Abstract: The present invention describes methods of treating dementia comprising administering an effective daily dose of N-[2-(6-fluoro-1H-indol-3-yl)ethyl]-3-(2,2,3,3-tetrafluoropropoxy)benzylamine to improve or augment the effect of an acetylcholinesterase inhibitor.
    Type: Grant
    Filed: September 6, 2017
    Date of Patent: May 26, 2020
    Assignee: H. LUNDBECK A/S
    Inventors: Ellen Schmidt, Johan Areberg
  • Patent number: 10653641
    Abstract: This invention relates to the use of CBD to treat mental disorders.
    Type: Grant
    Filed: September 8, 2016
    Date of Patent: May 19, 2020
    Assignee: GW Pharma Limited
    Inventors: Philip Robson, Geoffrey Guy, Stephen Wright, Emma Cheetham, Dominic Schiller
  • Patent number: 10646581
    Abstract: Described herein are prostate specific membrane antigen (PSMA) binding conjugates that are useful for delivering therapeutic, diagnostic and imaging agents. Also described herein are pharmaceutical composition containing them and methods of using the conjugates and compositions. Also described are processes for manufacture of the conjugates and the compositions containing them.
    Type: Grant
    Filed: May 25, 2018
    Date of Patent: May 12, 2020
    Assignee: Purdue Research Foundation
    Inventors: Philip S. Low, Sumith A. Kularatne
  • Patent number: 10624970
    Abstract: Described herein are prostate specific membrane antigen (PSMA) binding conjugates that are useful for delivering therapeutic, diagnostic and imaging agents. Also described herein are pharmaceutical composition containing them and methods of using the conjugates and compositions. Also described are processes for manufacture of the conjugates and the compositions containing them.
    Type: Grant
    Filed: May 25, 2018
    Date of Patent: April 21, 2020
    Assignee: Purdue Research Foundation
    Inventors: Philip S. Low, Sumith A Kularatne
  • Patent number: 10624971
    Abstract: Described herein are prostate specific membrane antigen (PSMA) binding conjugates that are useful for delivering therapeutic, diagnostic and imaging agents. Also described herein are pharmaceutical composition containing them and methods of using the conjugates and compositions. Also described are processes for manufacture of the conjugates and the compositions containing them.
    Type: Grant
    Filed: May 25, 2018
    Date of Patent: April 21, 2020
    Assignee: Purdue Research Foundation
    Inventors: Philip S. Low, Sumith A. Kularatne
  • Patent number: 10624969
    Abstract: Described herein are prostate specific membrane antigen (PSMA) binding conjugates that are useful for delivering therapeutic, diagnostic and imaging agents. Also described herein are pharmaceutical composition containing them and methods of using the conjugates and compositions. Also described are processes for manufacture of the conjugates and the compositions containing them.
    Type: Grant
    Filed: April 20, 2018
    Date of Patent: April 21, 2020
    Assignee: Purdue Research Foundation
    Inventors: Philip S. Low, Sumith A. Kularatne
  • Patent number: 10617693
    Abstract: The application pertains to methods of treating and/or preventing actinic keratosis, comprising administering a therapeutically effective amount of KX-01, to a subject in need thereof.
    Type: Grant
    Filed: March 12, 2018
    Date of Patent: April 14, 2020
    Assignee: Athenex, Inc.
    Inventors: Min-Fun Rudolf Kwan, Johnson Yiu-Nam Lau, E. Douglas Kramer, David Lawrence Cutler, Jane Fang
  • Patent number: 10617702
    Abstract: The invention relates to concentrated therapeutic phospholipid compositions; methods for treating or preventing diseases associated with cardiovascular disease, metabolic syndrome, inflammation and diseases associated therewith, neurodevelopmental diseases, and neurodegenerative diseases, comprising administering an effective amount of a concentrated therapeutic phospholipid composition.
    Type: Grant
    Filed: September 19, 2018
    Date of Patent: April 14, 2020
    Assignee: ACASTI PHARMA INC.
    Inventors: Fotini Sampalis, Henri Harland
  • Patent number: 10617684
    Abstract: An aqueous drug in which the chemical decomposition of the compound represented by formula (1) or of a salt thereof is inhibited, and a method for producing said aqueous drug. An aqueous drug provided with: a solution (liquid A) that contains the compound represented by formula (1) or a salt thereof and that has a pH of 5.3 or less; and a dilution liquid (liquid B) that is mixed with the liquid A in order to prepare a solution to be administered.
    Type: Grant
    Filed: June 2, 2016
    Date of Patent: April 14, 2020
    Assignee: KYORIN PHARMACEUTICAL CO., LTD.
    Inventors: Takahiro Goto, Hitoshi Kozuka, Mizuho Shibata
  • Patent number: 10610594
    Abstract: A topical dermatological/pharmaceutical composition is described that includes BPO wherein the composition is a wash composition with desirable tolerance, stability and foaming properties. The composition can include: a) benzoyl peroxide (BPO); b) at least one mild surfactant selected from anionic and/or non-ionic surfactant classes; c) zinc gluconate; d) dipotassium glycyrrhizate; and e) at least one gelling agent. The composition is preferably in the form of an aqueous gel or an aqueous-alcoholic gel. Also described, is the use of such a composition for the treatment of dermatological disorders, and in particular in the treatment of acne.
    Type: Grant
    Filed: November 13, 2013
    Date of Patent: April 7, 2020
    Assignee: GALDERMA S.A.
    Inventors: Karine Nadau-Fourcade, Fabienne Louis, Laetitia Mazeau